Reaction
Marrow Hyperplasia reporting signals
As of the last recalculation, Marrow Hyperplasia appears in 679 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is EPOETIN ALFA (PRR 53.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Epoetin Alfa | 20 | 53.3 | 53.4 |
| Romiplostim | 25 | 52.8 | 52.9 |
| Pyrazinamide | 14 | 46.6 | 46.7 |
| Rifampicin | 13 | 40.1 | 40.2 |
| Ganciclovir Sodium | 12 | 35.4 | 35.4 |
| Ganciclovir | 11 | 33.5 | 33.5 |
| Hydroxyurea | 22 | 32.9 | 33.0 |
| Atovaquone | 8 | 30.8 | 30.8 |
| Erythropoietin | 20 | 30.7 | 30.7 |
| Amphotericin B | 12 | 29.9 | 29.9 |
| Isoniazid | 15 | 29.0 | 29.0 |
| Daspone | 9 | 28.7 | 28.7 |
| Dapsone Gel, 5% | 9 | 28.7 | 28.7 |
| Dapsone | 9 | 26.2 | 26.2 |
| Imatinib | 14 | 24.8 | 24.8 |
| Eltrombopag Olamine | 17 | 23.2 | 23.2 |
| Iron Sucrose | 7 | 22.7 | 22.7 |
| Imatinib Mesylate | 17 | 19.1 | 19.2 |
| Filgrastim | 22 | 18.5 | 18.5 |
| Efavirenz | 6 | 16.6 | 16.6 |
| Azacitidine For | 9 | 15.4 | 15.4 |
| Deferasirox | 13 | 15.3 | 15.3 |
| Bosutinib | 4 | 13.7 | 13.7 |
| Daptomycin | 4 | 13.4 | 13.4 |
| Pegaspargase | 5 | 12.6 | 12.6 |
| Blinatumomab | 4 | 11.8 | 11.8 |
| Azacitidine | 10 | 10.5 | 10.5 |
| Dasatinib | 10 | 8.4 | 8.4 |